Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water
NCT ID: NCT00871806
Last Updated: 2021-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2009-04-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence Study of Nefopam Hydrochloride 30mg Tablets vs Acupan® 30mg Tablets in Healthy Subjects
NCT03311022
Bioequivalence Study of Idalopirdine Tablets 60 mg
NCT02371707
Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions
NCT01581775
Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin
NCT02750709
Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions
NCT00803764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eletriptan commercial tablet with water
Eletriptan commercial tablet given with water
Commercial tablet with water
40 mg tablet, given once to each subject
Eletriptan oral disintegrating tablet (ODT) #1 without water
Oral disintegrating tablet formulation #1 without water
ODT #1 without water
40 mg tablet given once to each subject
Oral disintegrating tablet formulation (ODT) #2 without water
Oral disintegrating tablet formulation #2 without water
ODT #2 without water
40 mg tablet given once to each subject
Oral disintegrating tablet formulation (ODT) #1 with water
Oral disintegrating tablet formulation (ODT) #1 with water
ODT #1 with water
40 mg tablet given once to each subject
Oral disintegrating tablet formulation (ODT) #2 with water
Oral disintegrating tablet formulation (ODT) #2 with water
ODT #2 with water
40 mg tablet given once to each subject
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Commercial tablet with water
40 mg tablet, given once to each subject
ODT #1 without water
40 mg tablet given once to each subject
ODT #2 without water
40 mg tablet given once to each subject
ODT #1 with water
40 mg tablet given once to each subject
ODT #2 with water
40 mg tablet given once to each subject
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No CYP3A4 inhibitors
Exclusion Criteria
* Positive urine drug screen
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1601122
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.